Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May 30;4(5):e214.
doi: 10.1038/bcj.2014.34.

The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas

R Briski  1 , A L Feldman  2 , N G Bailey  3 , M S Lim  3 , K Ristow  4 , T M Habermann  4 , W R Macon  2 , D J Inwards  4 , J P Colgan  4 , G S Nowakowski  4 , M S Kaminski  1 , T E Witzig  4 , S M Ansell  4 , R A Wilcox  1
Affiliations

The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas

R Briski et al. Blood Cancer J. .

Abstract

Peripheral T-cell lymphomas (PTCLs) are a heterogenous group of aggressive non-Hodgkin's lymphomas that are incurable in the majority of patients with current therapies. Outcomes associated with anthracycline-based therapies are suboptimal, but remain the standard of care for most patients, even though the benefits of this approach remain uncertain. This study retrospectively examined outcomes in a cohort of North American PTCL patients treated with both anthracycline- and nonanthracycline-containing regimens. The incorporation of anthracycline-containing regimens was associated with improved progression-free survival (PFS) and overall survival (OS). Patients treated with nonanthracycline-containing regimens were more likely to have high-risk features and were less likely to undergo high-dose therapy and stem cell transplantation. However, anthracycline use remained an independent predictor of improved PFS and OS when adjusting for these confounding variables. Anthracycline-based regimens and consolidation with high-dose therapy and autologous stem cell transplantation in appropriately selected patients remains a viable option for patients unable to participate in a clinical trial. Long-term disease-free survival is not optimal, highlighting the need for an improved understanding of disease pathogenesis, and the development of novel therapeutic strategies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Anthracycline-containing regimens are associated with improved survival in PTCLs. Progression-free survival (a, c) and overall survival (b, d) for all patients (a, b) and PTCL-NOS/AITL patients (c, d) treated with (—) and without (–-) an anthracycline.
Figure 2
Figure 2
Anthracycline-containing regimens are associated with improved survival in high-risk PTCL. Progression-free survival (a) and overall survival (b) for all patients treated with anthracycline-based combination chemotherapy regimens stratified by the IPI. Progression-free survival (c) and overall survival (d) in high-risk (IPI ⩾3) patients treated with (—) and without (–-) an anthracycline.
Figure 3
Figure 3
Anthracycline-containing regimens are associated with improved survival in the absence of stem cell transplantation. Overall survival for all patients (a) and PTCL-NOS/AITL patients (b) stratified by anthracycline use and stem cell transplantation status.
See this image and copyright information in PMC

References

    1. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–4130. - PubMed
    1. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481.
    1. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987–994. - PubMed
    1. Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;15:1467–1475. - PubMed
    1. Reiser M, Josting A, Soltani M, Staib P, Salzberger B, Diehl V, et al. T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors. Leuk Lymphoma. 2002;43:805–811. - PubMed

Publication types

LinkOut - more resources